STAT

The reinvention of Bob Hugin: Amid anger over drug prices, a former pharma CEO makes a run for the Senate

Bob Hugin, the former CEO of Celgene, has left behind conference halls and princely pay packages. Now: hot, sweaty campaign events in Jersey.
Bob Hugin, Republican candidate for Senate, exits a voting booth after casting his ballot in the New Jersey primaries in June.

RUTHERFORD, N.J. — Among the 30,000 attendees of the Rutherford Street Fair, sweating it out on the street between the zeppoles and deep-fried Oreos, was the pharmaceutical millionaire who wants to be their next senator.

Bob Hugin, the former CEO of Celgene, spent Labor Day walking through the crowd with a phalanx of staff and volunteers, each with a sign and a T-shirt bearing his name. They chanted, cheered, and sloganeered as Hugin’s would-be constituents looked on, varyingly bemused or befuddled at the merry little militia demonstrating in their town. Hugin shook hands, posed for photos, and remembered to say “good to see you” but never “nice to meet you.”

This is his life now. In February, the 64-year-old left behind the air-conditioned conference halls, sycophantic analysts, and princely pay packages that come with being a Fortune 500 CEO. He branded himself “a different kind of Republican,” set aside $20 million of his own money, and became the GOP’s only hope to unseat the incumbent Sen. Bob Menendez.

“To be honest with you, I wouldn’t be running if it wasn’t for him, because he’s wrong for New Jersey, and he’s

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks